Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vidutolimod - Checkmate Pharmaceuticals

X
Drug Profile

Vidutolimod - Checkmate Pharmaceuticals

Alternative Names: ARB 1598; CMP-001; CYT 003 QbetaG10; CYT-003; CYT003 PolQb; CYT003 PolQbeta; CYT003-QbG10; Immunodrug™ CYT003-QbG10; IND#18627; QbG10; Virus-like particle-based cancer vaccine - Checkmate Pharmaceuticals; VLP-based cancer vaccine - Checkmate Pharmaceuticals

Latest Information Update: 16 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytos Biotechnology
  • Developer Arbutus Biopharma; Bristol-Myers Squibb; Centre Hospitalier Universitaire Vaudois; Checkmate Pharmaceuticals; Cytos Biotechnology; Genocea Biosciences [CEASED]; Pfizer; Regeneron Pharmaceuticals; University of Pittsburgh
  • Class Allergy immunotherapies; Anti-inflammatories; Antiallergics; Antineoplastics; Cancer vaccines; Immunotherapies; Oligonucleotides; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Malignant melanoma
  • Phase II Head and neck cancer; Triple negative breast cancer
  • Phase I/II Lymphoma; Solid tumours; Squamous cell cancer
  • Suspended Merkel cell carcinoma
  • No development reported Colorectal cancer; Non-small cell lung cancer
  • Discontinued Allergic asthma; Atopic dermatitis; Hepatitis B; Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 16 Apr 2024 Suspended - Phase-II for Merkel cell carcinoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural) (NCT04916002) (EudraCT2023-507344-36-01)
  • 16 Apr 2024 Suspended - Phase-II for Squamous cell cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (Intratumoural) (NCT04916002) (EudraCT2023-507344-36-01)
  • 05 Apr 2024 Suspended - Phase-II for Merkel cell carcinoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (Intratumoural) (NCT04916002) (EudraCT2023-507344-36-01)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top